Cite
Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.
MLA
Masato Chiba, et al. “Efficacy of Irreversible EGFR-TKIs for the Uncommon Secondary Resistant EGFR Mutations L747S, D761Y, and T854A.” BMC Cancer, vol. 17, Apr. 2017, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-017-3263-z.
APA
Masato Chiba, Yosuke Togashi, Eri Bannno, Yoshihisa Kobayashi, Yu Nakamura, Hidetoshi Hayashi, Masato Terashima, De Velasco, M. A., Kazuko Sakai, Yoshihiko Fujita, Tetsuya Mitsudomi, Kazuto Nishio, Chiba, M., Togashi, Y., Bannno, E., Kobayashi, Y., Nakamura, Y., Hayashi, H., Terashima, M., & Sakai, K. (2017). Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. BMC Cancer, 17, 1–10. https://doi.org/10.1186/s12885-017-3263-z
Chicago
Masato Chiba, Yosuke Togashi, Eri Bannno, Yoshihisa Kobayashi, Yu Nakamura, Hidetoshi Hayashi, Masato Terashima, et al. 2017. “Efficacy of Irreversible EGFR-TKIs for the Uncommon Secondary Resistant EGFR Mutations L747S, D761Y, and T854A.” BMC Cancer 17 (April): 1–10. doi:10.1186/s12885-017-3263-z.